

| |
|---------------|
| Item: 11 |
| Enclosure: 15 |

| REPORT CLASSIFICATION | ✓ | CATEGORY OF PAPER | ✓ |
|--------------------------------|---|--------------------------|---|
| Official | ✓ | Proposes specific action | |
| Official: Sensitive Commercial | | Provides assurance | |
| Official: Sensitive Personal | | For information only | ✓ |

| BOARD MEETING | |
|--|---|
| 1 JULY 2022 | |
| Report Title: | Schedule of Meetings 2022/23 |
| Purpose of report | |
| To provide members with the Board meetings date for the remainder of the financial year for 2022/23. | |
| Key points | |
| <p>To ensure the Board has sufficient time to discharge its functions effectively and maintain oversight and assurance on those functions it has delegated, formal meetings have been scheduled on a bi-monthly basis. In addition, to allow protected time for the Board to undertake in-depth development and discussions on particular areas of focus, Board development/seminar sessions have also been scheduled for the year.</p> <p>The meeting dates are as follows:</p> | |
| Board Meeting (am) | Board development/ Seminar Sessions (pm) |
| 1 July 2022* | 26 July 2022** |
| 27 September 2022 | 27 September 2022 |
| 29 November 2022 | 29 November 2022 |
| 31 January 2023 | 31 January 2023 |
| 28 March 2023 | 28 March 2023 |
| <p><i>*This meeting will be held between 12.30-16.00 due to the nature of business required as part of the ICB's establishment on the 1 July 2022.</i></p> <p><i>**Please note the time of this session may also need to vary due to the requirement to hold an initial Integrated Care Partnership meeting on the same day.</i></p> <p>Members are asked to note the above dates and ensure their availability for these as much as possible. Where non-attendance cannot be avoided, the Board members are asked to ensure an appropriately nominated deputy is available to attend on their behalf.</p> | |
| Risks and issues | |
| The Board is at risk of not being quorate if members do not attend or send appropriate deputies. | |

| |
|----------------------|
| Item: 11 |
| Enclosure: 15 |

| Assurances | | | | | | |
|---|---|--|-----------|--|------------|---|
| Advance notification of meetings to facilitate diary management. | | | | | | |
| Recommendation/Action Required | | | | | | |
| The Board is asked to receive the Board dates for information. | | | | | | |
| Sponsor/approving director | C Riley, Executive Director of Corporate Governance, Communications and Involvement (Designate) | | | | | |
| Report author | D Cornell, Associate Director of Operations, South Tyneside | | | | | |
| Link to ICB corporate aims (please tick all that apply) | | | | | | |
| CA1: Improve outcomes in population health and healthcare | | | | | | ✓ |
| CA2: tackle inequalities in outcomes, experience and access | | | | | | ✓ |
| CA3: Enhance productivity and value for money | | | | | | ✓ |
| CA4: Help the NHS support broader social and economic development | | | | | | ✓ |
| Relevant legal/statutory issues | | | | | | |
| ICB Constitution and Standing Orders requirements | | | | | | |
| Any potential/actual conflicts of interest associated with the paper? (please tick) | Yes | | No | | N/A | ✓ |
| If yes, please specify | | | | | | |
| Equality analysis completed (please tick) | Yes | | No | | N/A | ✓ |
| If there is an expected impact on patient outcomes and/or experience, has a quality impact assessment been undertaken? (please tick) | Yes | | No | | N/A | ✓ |
| Key implications | | | | | | |
| Are additional resources required? | Not applicable, Board information only. | | | | | |
| Has there been/does there need to be appropriate clinical involvement? | Not applicable, Board information only. | | | | | |
| Has there been/does there need to be any patient and public involvement? | Not applicable, Board information only. | | | | | |
| Has there been/does there need to be partner and/or other stakeholder engagement? | Not applicable, Board information only. | | | | | |